GUIDELINE FOR THE USE OF RED BLOOD CELL PRODUCTS BASED ON SCIENTIFIC EVIDENCE (REVISION THIRD EDITION)
12) 1) 2) 12) 3) 12) 4) 12) 5) 12) 6) 12) 7) 12) 8) 12) 9) 12) 10) 12) 11) 12)
Authors
- Kazuhiro Nagai (ORCID: https://orcid.org/0009-0002-2335-4381)
- Toshiki Mushino (ORCID: https://orcid.org/0000-0001-7700-5262)
- Eisaburo Sueoka (ORCID: https://orcid.org/0000-0002-7930-9777)
- Masanori Matsumoto (ORCID: https://orcid.org/0000-0002-7243-3126)
- Midori Kumagawa (ORCID: https://orcid.org/0000-0003-4345-5876)
- Akihiko Yokohama (ORCID: https://orcid.org/0000-0001-8514-086X)
- Kohshi Ohishi (ORCID: https://orcid.org/0000-0001-8136-9907)
- Takashi Sonoki (ORCID: https://orcid.org/0000-0002-0211-3311)
- Yasunori Ueda (ORCID: https://orcid.org/0000-0002-4487-5808)
- K. Osaki
- Shikiko Ueno
Institutions
- Gunma University (JP)
- Saga University (JP)
- Wakayama Medical University (JP)
- Kurashiki Central Hospital (JP)
- Fukuoka University Hospital (JP)
- Mie University Hospital (JP)
- Nagasaki Medical Center (JP)
- Kumamoto University Hospital (JP)
- Nara Medical University (JP)
Publication Details
- Journal
- Japanese Journal of Transfusion and Cell Therapy
- Published
- 2024-12-20
- DOI
- https://doi.org/10.3925/jjtc.70.579
- Citations
- 2
- Primary Topic
- Biosimilars and Bioanalytical Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.48